Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageFresenius Medical Care is the world’s leading provider of products and services for individuals with kidney diseases based on publicly reported revenue. As a vertically integrated medical technology (MedTech) and healthcare service company, Fresenius Medical Care combines medical device engineering and manufacturing expertise with comprehensive patient care. The incidence of kidney disease is increasing worldwide. A significant rise in the drivers of kidney disease, such as obesity, diabetes, and hypertension, has elevated it to a global public health epidemic.
In the company’s own words · 20-F filed Feb 24, 2026 · SEC EDGAR
Fresenius Medical Care AG (FMS) reported revenue of €5.07B in Q4 2025 (quarter ended December 31, 2025), down 0.3% from the same quarter a year earlier. That came with a gross margin of 27% and net income of €327M (6.5% of revenue). For the full year FY2025, revenue was €19.6B (+1.5% year on year) and net income €978M.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Medical Care Facilities
Ranks #26 of 28 by Smart Score